Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nextgen Bioscience Inc. (NXGB) since 2008 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data at Nextgen Bioscience Inc.. Table 2 shows the detailed insider transactions. The reporting company's CIK number is 1343465.
Total stock buying since 2008: $0.
Total stock sales since 2008: $0.
Total stock option exercises since 2008: $0.
▪ Recent SEC 13D filings for NXGB
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
A schedule 13D must be filed with the SEC when a person or group of persons acquires beneficial ownership of more than 5% of Nextgen Bioscience Inc. (NXGB). A schedule 13D/A is an amendment that is filed when there are any material changes in beneficial ownership.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2008 | 22,000,000 | $0 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2008-01 | 22,000,000 | $0 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-01-31 | Oxon Life Science Ltd (10% Owner) | Buy | 22,000,000 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of NXGB listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nextgen Bioscience Inc. (symbol NXGB, CIK number 1343465) see the Securities and Exchange Commission (SEC) website.